![]() We look forward to advancing our epilepsy program as rapidly as possible so that we can provide new hope for patients suffering with intractable focal epilepsies."Įpilepsy is one of the most common chronic neurological diseases and, according to the Centers for Disease Control, affects more than 65 million people around the world of which 3.4 million are in the U.S. Michael Narachi, president and CEO of CODA, said, "These results are exciting as the quantitative relationship between receptor expression and efficacy helps to identify the target range for receptor dosing in development-related studies. "Importantly, our research showed that the expression of our lead receptor is highly correlated with a reduction in seizure frequency – the more receptor is expressed, the lower seizure frequency was." Together, these model systems replicate many features of human temporal lobe epilepsy," said Dr. "The results showed that CODA's lead receptor and activator drug significantly reduces seizure frequency in two different models of focal epilepsy - electrical seizure threshold and kainic acid induction. Doses of this small molecule activator can be adjusted to fine tune control of hyperactivity brain cell firing and suppress seizures without adverse effects. The data will be presented by Susan Catalano, Ph.D., CODA's chief science officer, at the 2022 Epilepsy Foundation Pipeline Conference being held June 5-6, 2022.ĬODA's approach to treating focal epilepsy is adeno-associated vector (AAV)-mediated delivery of a novel engineered inhibitory ion channel that is activated by binding to an orally bioavailable small molecule drug. Data also demonstrated that the expression of CODA's lead receptor is highly correlated with a reduction in seizure frequency. ![]() Results showed that the rapid reduction in seizures is consistent with the pharmacokinetics of the activator drug in mouse models. ![]() ("CODA"), a preclinical-stage biopharmaceutical company using a chemogenetic platform to treat prevalent intractable neurological disorders, today announced that preclinical data from the Company's focal epilepsy program demonstrated that treatment with the Company's lead engineered receptor and small molecule activator drug significantly reduced focal seizure frequency in vivo. SOUTH SAN FRANCISCO, Calif., J/PRNewswire/ - CODA Biotherapeutics, Inc. “These lower quality companies and programs, they’re going to be shut down,” Mike Rice, Life Sci Advisors told BioSpace when discussing the “brutal” financing environment.īioSpace has contacted CODA’s former exec team for comment but has not received a response.Data presented at 2022 Epilepsy Foundation Pipeline Conference provide additional in vivo proof of concept for CODA's engineered receptors and activator drugs in controlling seizures The immediate liquidity will keep Sorrento afloat for now. In February, Sorrento Therapeutics received interim court approval for a $75 million financing through Chapter 11 bankruptcy. In addition to staff cuts, companies are making tough financial calls to keep the doors open. That’s more than a 100% increase compared to the 10 announced in 2021. More than 35 companies have already been added to BioSpace’s Layoff Tracker for 2023.Ĭuts first started to accelerate in 2022, as 28 U.S.-headquartered public pharma and biotech companies made official downsizing announcements, according to a report shared with BioSpace from LifeSci Communications. ![]() Companies of all sizes are making cuts to make ends meet. While the reason for CODA’s shuttering has not been disclosed, biopharma is facing an era of slim funding across the board. Its initial targets focused on focal epilepsy and chronic neuropathic pain. According to her profile, Catalona moved from CODA to Capsida Biotherapeutics in February.ĬODA has been working on a novel chemogenetic gene therapy platform to treat intractable neurological diseases. Susan Catalona left her CEO role at Cognition Therapeutics after 14 years last March to take on the CSO role at CODA. CODA’s SVP of drug discovery, Steve Dodson, started at Aeovian Pharmaceuticals in November 2022. In October 2022, Keravala moved up the ladder to CSO at Genescence Corporation. While no official statement has come out, Google shows the company as “permanently closed.” CODA’s website still exists but it appears the top execs started jumping ship as early as last fall.Īccording to her LinkedIn profile, the first to go was SVP of gene therapy, Annahita Keravala. In tough market, CODA quietly shuts doorsĪs life science companies feel the burn of the current economy, one Bay Area biotech, CODA Biotherapeutics, quietly shut its doors. ![]()
0 Comments
Leave a Reply. |